Shop

Iso – Accutane 20mg 50 Tablets Beligas Pharma INT

$50.00

Buy Iso-Accutane 20mg (50 Tabs) by Beligas Pharma – Premium acne treatment at just $45! Worldwide shipping from international warehouse. FDA-approved isotretinoin for severe acne & steroid-related breakouts. Secure checkout & discreet delivery.

Iso – Accutane 20mg 50 Tablets Beligas Pharma INT

$50.00

Add to cart
Buy Now
SKU: iso-accutane-20mg-50-tablets-beligas-pharma-int Category:

Substance: Isotretinoin
Manufacturer: Beligas Pharmaceuticals
Pack: 50 tabs (20mg/tab)

What is Isotretinoin?

Isotretinoin (brand name Accutane) is a powerful oral retinoid primarily used to treat severe acne. It works by shrinking oil glands and reducing skin inflammation.

Benefits for Bodybuilders:

Eliminates steroid-induced acne (common with Testosterone/Trenbolone)
Reduces oily skin (lowers sebum production by 90%)
Prevents cystic acne (deep, painful breakouts from androgens)

Usage Protocol:

  • Standard Dose: 0.5-1mg/kg bodyweight daily (e.g., 40-80mg/day for 80kg users)

  • Cycle Length: 4-6 months (cumulative dose determines long-term remission)

  • Best Taken With: Fatty meal (increases absorption by 60%)

Potential Side Effects:

Severe dryness (lips, eyes, nasal passages)
Elevated liver enzymes (requires monthly blood tests)
Depression/mood changes (controversial but documented)
Photosensitivity (higher sunburn risk)

Who Should Avoid It?

Pregnant women (high risk of birth defects)
Those with liver/kidney disease
Patients with history of depression
People on tetracycline antibiotics

Bodybuilding-Specific Notes:

  • Synergistic with steroids but may worsen joint pain (combine with omega-3s)

  • Avoid vitamin A supplements (risk of hypervitaminosis)

  • Bloodwork required (monitor triglycerides/LFTs monthly)

Customer reviews
0
0 ratings
5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Reviews

There are no reviews yet.

Write a customer review
Be the first to review “Iso – Accutane 20mg 50 Tablets Beligas Pharma INT”

Your email address will not be published. Required fields are marked *

0